Financials data is unavailable for this security.
View more
Year on year Lytix Biopharma AS 's revenues fell -63.82% from 11.03m to 3.99m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 56.07m to a larger loss of 87.90m.
Gross margin | -- |
---|---|
Net profit margin | -- |
Operating margin | -- |
Return on assets | -- |
---|---|
Return on equity | -- |
Return on investment | -- |
More ▼
Cash flow in NOKView more
In 2023, cash reserves at Lytix Biopharma AS fell by 67.19m. However, Cash Flow from Investing totalled 29.73m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 95.97m for operations while cash used for financing totalled 943.00k.
Cash flow per share | -- |
---|---|
Price/Cash flow per share | -- |
Book value per share | 1.19 |
---|---|
Tangible book value per share | 1.19 |
More ▼
Balance sheet in NOKView more
Current ratio | 4.61 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.0506 |
---|---|
Total debt/total capital | 0.0482 |
More ▼